newsfilter
← Latest News
GlobeNewswire·

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from